Beam Therapeutics (BEAM) Current Deferred Revenue (2020 - 2026)

Beam Therapeutics (BEAM) has 7 years of Current Deferred Revenue data on file, last reported at $304000.0 in Q1 2026.

• Quarterly Current Deferred Revenue fell 99.64% year-over-year to $304000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $304000.0 (down 99.64% YoY) and the FY2025 annual result came in at $6.7 million, down 95.31% from the prior year.
• Current Deferred Revenue fell to $304000.0 in Q1 2026 per BEAM's latest filing, from $6.7 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $338.2 million in Q4 2022 and bottomed at $304000.0 in Q1 2026.
• The 5-year median for Current Deferred Revenue is $115.0 million (2022), against an average of $121.4 million.
• The widest annual swing landed in 2022, when Current Deferred Revenue soared 1147.09%; it then sank 99.64% in 2026.
• Tracing BEAM's Current Deferred Revenue over 5 years: stood at $338.2 million in 2022, then sank by 47.19% to $178.6 million in 2023, then decreased by 20.45% to $142.1 million in 2024, then plunged by 95.31% to $6.7 million in 2025, then plunged by 95.43% to $304000.0 in 2026.
• Per Business Quant, the three latest BEAM Current Deferred Revenue figures stand at $304000.0 (Q1 2026), $6.7 million (Q4 2025), and $110.3 million (Q3 2025).

Peer Comparison